Methodology: what this review is and isn’t

This is a synthesis of published research and publicly available research-community reporting, not a hands-on trial. We did not administer MOTS-C to anyone, and nothing on this page should be read as a first-hand “before and after” account. The evidence is organized into three tiers so you can see exactly how strong (or weak) each claim’s backing actually is:

• Tier 1 — verified published sources: peer-reviewed studies and registered clinical trials, cited to their original source (PubMed Central, ClinicalTrials.gov), checked live as of October 2026.
• Tier 2 — community-reported patterns: recurring themes from research-forum and self-research discussion, described honestly as self-reported and uncontrolled, never presented as proof of effect.
• What’s missing: there is currently no published, controlled, human “before and after” trial of exogenous (injected) MOTS-C for any outcome. That gap is the single most important thing to understand before reading further.

Last updated: October 2026.

The core problem with “before and after” searches for MOTS-C

Almost everything published on MOTS-C to date falls into one of two categories, and neither one is a human trial of injecting the peptide:

1. Endogenous MOTS-C research — studies measuring the MOTS-C your own mitochondria already produce, and how those levels change with exercise, aging, or metabolic stress. This tells you about the peptide’s biology, not about what happens if you inject more of it.
2. Preclinical and early-phase research — animal studies and a small number of early human trials looking at specific biomarkers (like insulin sensitivity), not subjective “before and after” outcomes like body composition or energy.

Every “before and after” account you’ll find framed as a personal research log on forums or social media is self-reported, unblinded, and not independently verified. That doesn’t make every report false, but it does mean none of it currently rises above Tier 2 evidence.

Tier 1: What’s actually been published

Exercise raises your own MOTS-C — this is the best-established finding

The clearest, most replicated finding in MOTS-C research has nothing to do with injecting it. A 2020 open-access review in Frontiers in Physiology synthesizes research showing that circulating MOTS-C levels rise in response to acute and chronic exercise, tracking with other exercise-induced metabolic adaptations (PMC7817689). This is a real, published, peer-reviewed pattern. It is evidence that MOTS-C is part of how the body responds to exercise — it is not evidence about what happens when MOTS-C is injected exogenously in humans, which is a biologically different scenario (bypassing the body’s own regulated production and timing).

Circulating MOTS-C and insulin resistance: an observational link, not a before/after result

A separate line of observational research has looked at circulating MOTS-C levels in people with and without insulin resistance and metabolic syndrome, reported in a study indexed on PubMed Central (PMC12468430). This kind of research can show an association (lower MOTS-C levels showing up alongside worse metabolic markers in some cohorts) but it cannot show causation, and it says nothing about what supplementing MOTS-C would do to those markers. Observational correlation is a hypothesis-generating finding, not a before-and-after result.

The actual human dosing trial is still recruiting — there is no results data yet

As of October 2026, the relevant registered human study is a Phase 2 trial evaluating MOTS-C for improving insulin sensitivity, listed on ClinicalTrials.gov as actively recruiting (NCT07505745). This is the closest thing to a real “before and after” study design for exogenous MOTS-C that currently exists in the public record — and it has not reported results. Anyone telling you what this trial “found” is either confused about its status or making it up. Check the listing directly for the current status before trusting any secondary claim about it.

Tier 2: What research-community reports describe (read this section skeptically)

Across self-research forums and peptide-research discussion communities, a handful of self-reported themes come up repeatedly in research logs. We’re naming them because avoiding the topic entirely would leave readers to find worse, less-caveated versions elsewhere — not because they’re established findings. Each one is exactly as reliable as any other unverified, unblinded, self-reported account: not very.

• Subjective energy/endurance reports during exercise-adjacent research protocols, consistent in direction with (but not proof of) the published exercise-MOTS-C association above.
• Mixed reports on appetite and body composition over multi-week self-research periods, with no consistent pattern across reports and no controlled comparison group.
• Injection-site reactions (mild, temporary) reported occasionally, consistent with what’s generally reported for subcutaneously administered peptides.

None of this is a substitute for controlled data. If a vendor or reviewer shows you a “before and after” photo or chart tied to MOTS-C use, treat it the same way you’d treat any uncontrolled, unblinded self-report: interesting as an anecdote, not evidence of what the compound does.

A compliance note the “before and after” search crowd often skips

Two regulatory facts matter here and are frequently left out of hype-driven content: MOTS-C has been placed on the World Anti-Doping Agency’s Prohibited List as a metabolic modulator (AMPK pathway activator), meaning competitive athletes subject to WADA testing cannot use it. Separately, the regulatory status of MOTS-C under the FDA’s bulk drug substance frameworks has been unsettled and subject to change — researchers should verify current status independently rather than relying on any single source, including this one, to stay current indefinitely.

What this means if you’re trying to evaluate MOTS-C research claims

Put plainly: the published science establishes that MOTS-C is a real, biologically active mitochondrial-derived peptide involved in exercise response and metabolic regulation. It does not yet establish what a specific injected dose does to any human outcome over any specific timeframe — that trial is still recruiting. Any “before and after” content you encounter that states otherwise is going beyond what the current literature supports, regardless of how confident it sounds.

Frequently asked questions

Is there a real clinical “before and after” study of MOTS-C?

Not yet with published results. A Phase 2 trial (NCT07505745) is recruiting as of October 2026 and is designed to test MOTS-C’s effect on insulin sensitivity, but no results have been reported. Check the ClinicalTrials.gov listing directly for the current status.

Do the “before and after” photos and reports online mean anything?

They’re self-reported, unblinded, and not independently verified, so they sit well below the level of evidence a controlled trial would provide. They may reflect a real individual experience, but they can’t tell you what MOTS-C does on average, or separate its effect from other variables (diet, training changes, expectation effects) happening at the same time.

Does exercise really raise MOTS-C levels?

Yes — this is one of the better-supported findings in the literature, documented across multiple studies synthesized in a 2020 Frontiers in Physiology review. It describes the body’s own production of MOTS-C in response to exercise, not the effects of injecting additional MOTS-C.

Is MOTS-C banned for athletes?

Yes. WADA lists MOTS-C on its Prohibited List as a metabolic modulator. Athletes subject to WADA or affiliated testing should treat it as a banned substance.

Why doesn’t this page just show a before and after result?

Because one doesn’t exist in the controlled, published literature yet. We’d rather tell you that plainly than manufacture confidence the research doesn’t support.